M. Magrey Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (4)

5× Case Western Reserve University, University Hospitals, Cleveland, United States of America
1× Rheumatology, Case Western Reserve University, University Hospitals, Cleveland, Ohio, États-Unis
1× Case Western Reserve University, MetroHealth Medical Center, Cleveland, United States of America
1× Case Western Reserve University School of Medicine, Rheumatology, Cleveland, United States of America

Papers 8 stored

All · Aachen affiliation only

Le bimekizumab a démontré une efficacité comparable à 1 an chez les hommes et femmes atteints de spondyloarthrite axiale : résultats de deux études de Phase III
2025 Revue du Rhumatisme article Medicine Spondyloarthritis Studies and Treatments

0

citations
POS0788 BIMEKIZUMAB DEMONSTRATED SUSTAINED EFFICACY AND SAFETY ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION
2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

1

citations
POS0920 BIMEKIZUMAB DEMONSTRATES COMPARABLE ONE-YEAR EFFICACY IN MALE AND FEMALE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

0

citations
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
2024 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments

2

citations
AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB
2023 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
POS0664 DEFINING THRESHOLDS OF PRESENTEEISM MEASURES FOR UNACCEPTABLE WORK PARTICIPATION IN AxSpA
2023 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
2023 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

5

citations

8 results

M. Magrey ▲ Sign in to save

Departments & institutes in Aachen

Papers 8 stored

M. Magrey Sign in to save